Kolexia
Loirat Delphine Oncologie médicale
Loirat Delphine
Oncologie médicale
Clcc Institut Curie
Paris, France
205 Activités
369 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs du sein triple-négatives Métastase tumorale Cellules tumorales circulantes Récidive tumorale locale Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Carcinome épidermoïde

Collaborateurs

Voir plus
Pierga Jean-Yves
Pierga Jean-Yves
Clcc Institut Curie, Paris, France
Dieras Veronique
Dieras Veronique
Clcc Institut Curie, Paris, France
Le Tourneau Christophe
Le Tourneau Christophe
Clcc Institut Curie, Paris, France
Vincent-Salomon Anne
Vincent-Salomon Anne
Clcc Institut Curie, Paris, France

Industries

Voir plus
MSD
31 collaboration(s)
Dernière en 2023
Novartis
26 collaboration(s)
Dernière en 2023
Gilead
19 collaboration(s)
Dernière en 2023
AstraZeneca
13 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
TUC-TOC: Tucatinib in Combination With Oral Etoposide (VP16) - Trastuzumab in Patients With Metastatic HER2+ Breast Cancer After Progression Under Tucatinib-Capecitabine-Trastuzumab or Toxicity Related to Capecitabine: a Multicenter Phase II
Essai Clinique (Seagen)   07 mars 2024
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   29 février 2024
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis.
Oncogene   27 février 2024
SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control
Essai Clinique (Institut Curie)   15 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
ALCINA: Analysis of Circulating Tumor Markers in the Blood
Essai Clinique (Institut Curie)   01 février 2024
RadioPARP: A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (Triple Negative Breast Cancer) or Patient With Operated TNBC With Residual Disease
Essai Clinique (AstraZeneca)   29 janvier 2024
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial.
European journal of cancer (Oxford, England : 1990)   28 janvier 2024
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Nature communications   12 décembre 2023
Stratégies thérapeutiques du cancer du sein en cours de grossesse
Edimark   28 novembre 2023